SecBot SecBot

IMCR

Immunocore Holdings plc
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. X0· CIK 0001671927 Biotech & Drug Discovery
$28.88 −1.06 (−3.54%)
Nov 16 4:00 PM ET · prev $29.94
Market cap
$1.6B
Small cap
Consensus
Buy
74% Buy or better · 19 analysts
Median target
$57.50
+99% · range $33.00–84.00
1 year
−21.0%
from $36.57 · Nov 17
30 days
−3.2%
from $29.84
52-week range
$27.79–40.22
−28% from high · low Jun 8
Avg volume 20D
527.2K
Nov 6 spike 1.53M
Short interest
7.79M
≈15.1% of shares · −0.1%
Days to cover
14.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 2 exits
Filing reports
8
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 1 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 7/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 18 added (0 new), 14 trimmed or exited.

  • AnalystsBULLISH

    14 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.171 → −$0.194 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −0.1% to 7.79M shares. 14.2 days to cover, ≈15.1% of shares.

  • TrendRANGE

    7% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
2
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCADD1,597,037$50.7M
BlackRock, Inc.ADD1,004,598$31.9M
MARSHALL WACE, LLPDOUBLED590,941$18.8M
CITADEL ADVISORS LLCDOUBLED566,761$18.0M
Candriam S.C.A.ADD373,046$11.8M
Legal & General Group PlcADD299,670$9.5M
MORGAN STANLEYTRIM187,850$6.0M
Caption Management, LLCTRIM172,503$5.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 74% rate it Buy or better
Strong Buy4Buy10Hold5Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +99%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 26, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 3, 2026Mizuho
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
May 27, 2026
Herbst Roy Steven
Director
May 27, 2026
AWARD27,492 sh
May 27, 2026
Bell John Irving
Director
May 27, 2026
AWARD27,492 sh
May 27, 2026
Peterson Kristine
Director
May 27, 2026
AWARD27,492 sh
May 27, 2026
Ratcliffe Peter John
Director
May 27, 2026
AWARD27,492 sh
May 27, 2026
Pao William
Director
May 27, 2026
AWARD27,492 sh
May 27, 2026
Kaul Siddharth
Director
May 27, 2026
AWARD27,492 sh

Earnings setup

Estimates
−$0.19
EPS estimate, this quarter
−14%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.44–$0.01-8.2%$112.3M
Next Q-$0.11-$0.22–-$0.03-19.1%$119.9M
Current FY-$0.20-$0.32–-$0.03-390.1%$437.2M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
7,793,995
shares short
-0.1%
vs prior settlement
14.2
days to cover
≈15.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

8 filings · 6 press releases · 2 bullish · 1 bearish · 1 mixed · 4 neutral
All IMCR filing & press-release reports (14)